A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants
Clinical trial NCT06215430 · COMPLETED
Trial details
- NCT number
- NCT06215430
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-11
- Primary completion
- 2021-04-15
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.